Balyasny Asset Management LLC Xilio Therapeutics, Inc. Transaction History
Balyasny Asset Management LLC
- $54.9 Billion
- Q2 2024
A detailed history of Balyasny Asset Management LLC transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 272,486 shares of XLO stock, worth $204,364. This represents 0.0% of its overall portfolio holdings.
Number of Shares
272,486
Previous 338,542
19.51%
Holding current value
$204,364
Previous $365,000
29.32%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding XLO
# of Institutions
33Shares Held
12.6MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA3.79MShares$2.84 Million0.74% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3MShares$2.25 Million0.09% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.08 Million20.01% of portfolio
-
Morgan Stanley New York, NY1.11MShares$834,5550.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA903KShares$676,8980.0% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $20.6M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...